News

Jeffrey B. Kindler, chief executive officer and chairman of the board of Pfizer Inc., received the Glaucoma Research Foundation Catalyst Award.

Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advance in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.

Reichert Inc. has restructured its marketing function in an effort ?to meet the growing demands of the company?s vast product portfolio and improve performance through better focus and accountability,? according to Jerry C. Cirino, chairman and chief executive officer.

Alcon Laboratories is purchasing rights in the United States for two FDA-approved topical eye care products, difluprednate ophthalmic emulsion 0.05% (Durezol) and ganciclovir ophthalmic gel 0.15% (Zirgan), from Sirion Therapeutics Inc.

Ophthalmologists, ophthalmic organizations, and companies operating in the ophthalmology arena are contributing to efforts to assist Haiti respond to and recover from the earthquake that occurred in January.

John T. Flynn, MD, credits those who have contributed to the understanding of retinopathy of prematurity in the past, are currently active, and whose work is laying the groundwork for future breakthroughts.

Findings from recent studies indicate fundus autofluorescence imaging has useful diagnostic and prognostic applications in the clinical management of age-related macular degeneration.

An updated analysis of data from an ongoing phase II study of intravitreal ranibizumab treatment for diabetic macular edema shows that functional and anatomic benefits observed at 6-month primary efficacy endpoint are generally maintained at 1 year after switching to a "prn" dosing schedule.

Alcon Laboratories' Independent Director Committee is calling Novartis' merger proposal "grossly inadequate," and it is vowing to fight Novartis in its efforts to take control.

A single sustained-release dexamethasone intravitreal implant resulted in resolution of inflammation and improvement in visual acuity (VA) in patients with intermediate or posterior uveitis through 26 weeks in a multicenter, randomized, controlled clinical trial.

Pooled results from two randomized, investigator-masked parallel group clinical trials show that the fixed combination fo brimonidine tartrate 0.2%-timolol maleate 0.5% produced greater IOP lowering than the fixed combination of dorzolamidehydrochloride 2%-timolol maleate 0.5%, whether the fixed combination products were used alone or as an adjunct to treatment with a prostaglandin analogue.

A handheld applanation tonometer is a newer portable device for measuring IOP that has been designed for reliable performance and easy, economical use.

In response to an FDA warning of cleaning validation at one of its plants, Abbott Medical Optics said problematic manufacturing processes were restricted to production of its ophthalmic viscosurgical device, 3% sodium hyaluronate, which is no longer being made or sold.